Global ETD Search

31	Concentração plasmática da grelina total, grelina acetilada, leptina, GH e IGF-I em crianças e adolescentes com doença renal crônica / Plasma levels of acylated and total ghrelin in pediatric patients with mild to severe chronic kidney disease Naufel, Maria Fernanda Soares [UNIFESP] 29 July 2009 (has links) (PDF) Made available in DSpace on 2015-07-22T20:49:46Z (GMT). No. of bitstreams: 0 Previous issue date: 2009-07-29 / Background The mechanisms responsible for the uraemic anorexia are poorly understood. In children and adults with chronic kidney disease (CKD) increased levels of the orexigenic hormone ghrelin are often found. However, no data exits in relationship to concentration of acylated ghrelin in pediatric patients with CKD. Methods Cross-sectional study of acylated and total ghrelin plasma levels in pediatric patients with mild CKD undergoing conservative treatment (MCKD group, n = 19) and patients with end stage renal disease undergoing hemodialysis (ESRD group, n = 24) compared with healthy controls (n =20). The correlations between total or acyl ghrelin with leptin, GH, IGF-I, glomerular filtration rate (GFR) and anthropometric and nutritional measurements were also undertaken. Results ESRD patients had significantly lower BMI Z-score and energy intake while both ESRD and MCKD groups had lower height-for-age Z-score than control group. ESRD patients also exhibited higher total ghrelin levels (2009.7±1278.0 pg/ml, mean±SD) than either MCKD (1117.5±891.9 pg/ml) or controls (655.3±255.6 pg/ml). However, plasma acyl ghrelin levels did not differ between groups. The ESRD group had normal GH but low IGF-I levels. When all 43 uraemic subjects were combined, total ghrelin correlated positively with GH (r =0.340, p=0.0255) and negatively with IGF-I (r= - 0.415, p=0.0057) and GFR (r= -0.534, p<0.0002). Both total and acyl ghrelin correlated negatively with nutritional status. Conclusion The present findings suggest that most of the increased total ghrelin in CKD pediatric patients is desacylated. As desacyl ghrelin has been shown to inhibit feeding, its high levels may contribute to malnutrition and growth deficit in CKD patients. / TEDE / BV UNIFESP: Teses e dissertações Adolescentes Crianças Doença renal crônica Estado nutricional Grelina Leptina Fator de crescimento Insulin-Like I Desnutrição Chronic kidney failure Ghrelin Leptin Malnutrition Child Insulin-like growth factor I Nutritional status Adolescent
32	A N-acetilcisteína atenua a progressão da doença renal crônica / N-acetylcysteine attenuates the progression of chronic kidney disease Maria Heloisa Massola Shimizu 01 December 2005 (has links) Os biomarcadores do estresse oxidativo encontram-se elevados na urina e no plasma dos pacientes renais crônicos. A aldosterona (ALD) contribui para a lesão renal no modelo de rins remanescentes. Objetivos: 1- Determinar o efeito do antioxidante N-acetilcisteína (NAC) sobre a função renal e a aldosterona plasmática de animais com IRC. 2- Avaliar o efeito da NAC sobre a evolução da IRC, mesmo quando administrada tardiamente. 3- Avaliar os efeitos da NAC associada a Espironolactona (Spi). Material e Métodos: Ratos adultos Wistar machos foram submetidos a nefrectomia de 5/6 (Nx). No estudo 1: Animais foram tratados ou não com NAC na dose de (600mg/l na água de beber) iniciado 7dias após nefrectomia (Nx). Estudos de clearance foram realizados em todos os grupos, 21, 60 e 120 dias após Nx. No estudo 2: 6 animais foram tratados com NAC após 60 dias de Nx e estudados 120 dias após NX. No estudo 3: Os ratos foram tratados com Spi (1.5g/kg de dieta) associados ou não com NAC, ambos iniciados a partir do 7º dia da nefrectomia e estudados 60 dias após a Nx. Em todos os grupos foram avaliados: clearance de inulina (RFG, ml/min/100g peso); proteinúria (Uvpr., mg/24h); aldosterona plasmática (ng/dl); relação potássio/sódio urinário (UK/UNa), pressão arterial (mmHg), TBARS urinário (nmoles/24h) e o índice de glomeruloesclerose (%). Resultados: A ingestão média de NAC foi similar nos respectivos grupos tratados. Significante diminuição de TBARS (marcador de peroxidação lipídica), foi observada nos ratos Nx tratados com NAC (mesmo quando administrado tardiamente). O principal resultado deste estudo foi que a administração de NAC nos animais com nefrectomia de 5/6, protegeu a filtração glomerular (GFR) significativamente, com uma média de clearance de inulina de 0.45 ml/min (50% dos valores normais), mantendose estável 120 dias após a nefrectomia (0,51 ± 0,03). Ao contrário, GFR diminuiu progressivamente nos animais não tratados (0,16 ± 0,03). Nos animais Nx+NAC, a proteinúria, o índice de glomeruloesclerose e a pressão arterial, apresentaram diminuição após 120 dias de Nx e hipertrofia dos corações e das adrenais foram atenuadas. Estes efeitos benéficos estão associados com uma significante redução da aldosterona plasmática e da razão UK/UNa (marcador indireto da ação tubular da aldosterona) e foram observados mesmo com a administração tardia de NAC (60 dias após Nx). A mortalidade foi de 33% no grupo de Nx120, 25% no grupo Nx120+NAC e 10% nos animais Nx120+60NAC. No estudo 3: A espironolactona isoladamente diminuiu a proteinúria dos animais Nx, entretanto, quando associada a NAC promoveu maior proteção da filtração glomerular (Nx60 + NAC+Spi = 0,59±0,04 vs.Nx + 60 + NAC = 0,47 ± 0,05, p < 0,001) e menor pressão arterial (136±2mmHg) do que nos animais tratados apenas com NAC (154 ± 2 mmHg). Conclusões: 1. O antioxidante NAC exerceu efeito protetor sobre a filtração glomerular de ratos com insuficiência renal crônica, mesmo quando administrado tardiamente, além de diminuir as concentrações de aldosterona e TBARS, marcador de peroxidação lipídica. 2. A associação de NAC e espironolactona proporcionou efeito benéfico aditivo sobre a filtração glomerular, acompanhado de uma maior queda da pressão arterial. / Oxidative stress biomarkers are increased in urine and plasma from renal chronic patients. Aldosterone (ALD) contributes to the kidney lesion in the remnant kidney model. Objectives: This studies was carried out to: 1- Determine the effect of antioxidant N-acetylcysteine (NAC) on kidney function and plasma aldosterone on animals with chronic renal failure (CRF); 2- Evaluate the effect of NAC on the CRF evolution, even when administered at a later stage; 3- Evaluate the effects of NAC associated with spironolactone (SPI). Material and Methods: Adult male Wistar rats were submitted to 5/6 nephrectomy (Nx). In study 1: Animals were treated or not with NAC (600 mg/l in drinking water), started 7 days after Nx. Clearance studies were performed on all rats at 21, 60 and 120 days after Nx. In study 2: 6 rats were treated with NAC initiated 60 days after Nx and studied 120 days after Nx. In study 3: rats were treated with Spi (1.5 g/Kg diet) associated or not to NAC, both initiated 7 days after Nx-treated rats and studied 60 days after Nx. In all experiments the following were measured: inulin clearance (GRF, ml/min/100g body weight); proteinuria (Uvpr, mg/24h); plasma aldosterone (ng/dl); urinary potassium/sodium ratio (UK/UNa); blood pressure (mmHg); urinary TBARS (nmoles/24h) and glomerulosclerosis index (%). Results: Mean daily NAC ingestion was similar in respective treated groups. A significant decrease in urinary TBARS (an index of lipid peroxidation) was observed in the NAC treated rats even when administered at a later stage. The main new finding of this study is that NAC administration to 5/6-Nx rats protects the glomerular filtration rate (GFR) significantly, with a mean inulin clearance of 0.45 (50% of the normal values), remaining stable 120 days following nephrectomy (0.51±0.03). Conversely, GFR fell progressively in untreated rats (0.16±0.03). In Nx+NAC rats, proteinuria, glomerulosclerosis index and blood pressure all decreased by day 120, and heart and adrenal hypertrophy were attenuated. These beneficial effects were associated with a significant reduction in plasma aldosterone and urinary sodium/potassium (UK/UNa) ratio (indirect marker of aldosterone tubular action) and were observed even when NAC was administered later (60 days after Nx). Mortality was 33% in the Nx 120 group, 25% in the Nx120+NAC group and 14.3% in the Nx120 (Nx60+60NAC). In study 3: Spironolactone isolatedly decreased proteinuria in the Nx animals, however when associated with NAC it caused more protection of GFR (Nx60+NAC+Spi = 0.59±0.04 vs Nx60+NAC = 0.47 ± 0.05, p < 0.001) and lower blood pressure (136±2 mmHg) than in the animals treated only with NAC (154±2 mmHg). The combination of Spi and NAC lowered blood pressure and improve GFR protection. Conclusion: 1. In the remnant kidney model, NAC has a protective effect attributable to decreased plasma aldosterone and lower of lipid peroxidation indicative of thiobarbituric acid reactive substances (TBARS) lower levels, even in the later stages. 2. Combination of NAC and Spi showed an extra beneficial effect over glomerular filtration, and a higher decrease of blood pressure. Acetilcisteína Aldosterona Espironolactona. Insuficiência renal crônica Inulina Peroxidação de lipídeos Ratos Wistar Testes de função renal Acetylcysteine Aldosterone Chronic kidney failure Inulin Kidney function renal Lipid peroxidation Spironolactone Thiobarbituric acid reactive Wistar rats
33	Efeito da insulina glargina sobre o controle glicêmico e risco de hipoglicemia em pacientes portadores de diabetes mellitus tipo 2 e doença renal crônica estágios 3 e 4: ensaio clínico, controlado e randomizado / Insulin glargine effect on glycemic control and hypoglycemia risk in patients with type 2 diabetes mellitus and chronic kidney disease stages 3 and 4: a randomized, open-label controlled clinical trial Carolina de Castro Rocha Betonico 27 January 2017 (has links) Diabetes mellitus (DM) é uma das principais causas de doença renal crônica terminal. Na doença renal diabética (DRD) observa-se um curso bifásico no padrão glicêmico, na fase inicial o aumento da resistência insulínica induz a hiperglicemia e, com perda progressiva da taxa de filtração glomerular, há redução na depuração dos medicamentos anti-hiperglicemiantes e insulina, aumentando o risco de hipoglicemias. Portanto, diante da perda da função renal, a reavaliação da terapia hipoglicemiante e ajustes constantes nas doses de insulina são necessários, com intuito de otimizar o controle glicêmico e minimizar seus efeitos colaterais. A revisão da literatura mostra diversos pontos sem resposta, principalmente relacionados à dose, ajuste da terapia insulínica, seguimento e monitoração do controle glicêmico em portadores de DM e DRC. O objetivo deste ensaio randomizado, cruzado, controlado foi comparar o controle glicêmico do tratamento com insulina glargina à insulina NPH em portadores de DM2 e DRD estágios 3 e 4. Pacientes e métodos: Trinta e quatro pacientes foram randomizados para receber insulina glargina uma vez ao dia ou insulina NPH em três aplicações diárias. Insulina lispro foi prescrita três vezes ao dia, em aplicações pré-prandiais nos dois grupos. Após 24 semanas de terapia, os pacientes tiveram seu esquema de insulina trocado para terapia insulínica oposta. Testes laboratoriais foram realizados após 12, 24, 36 e 48 semanas de estudo. O sistema de monitorização continua de glicose (CGMS) foi instalado ao término de cada terapia. Resultados: Dos 34 pacientes incluídos, 29 completaram as 48 semanas propostas no estudo, 2 pacientes perderam seguimento por má adesão e 3 pacientes não completaram o estudo em decorrência a eventos adversos (1 óbito, 1 ingresso em hemodiálise e 1 evento cardiovascular, todos em uso de insulina NPH). Após 24 semanas de tratamento com insulina glargina houve uma redução estatisticamente significante da média da HbA1c de 8,86 ± 1,4% para 7,95 ± 1,1% (p=0,0285), esta diferença não foi observada com a insulina NPH (8,21 ± 1,29% para 8,44 ± 1,32%). Durante o uso de insulina glargina o número de eventos noturnos de hipoglicemia foi menor comparado a insulina NPH (p=0,046); além disso, hipoglicemia grave ocorreu apenas na terapêutica com NPH. Conclusão: O tratamento com insulina glargina foi associado a melhor controle glicêmico e a redução do risco de hipoglicemia noturna quando comparada à insulina NPH,em pacientes portadores de DM e DRC estágios 3 e 4 / Diabetes mellitus is the leading cause of chronic kidney disease (CKD). Kidney disease diagnosis and its progression require re-evaluation of hypoglycemic therapy and constant dosing adjustments, to optimize glycemic control and minimize its side effects. Long acting insulin analogs and its pharmacokinetics have not been studied in different stages of kidney disease, nor is there consensus defining appropriate dose adjustment in patients with type 2 diabetes (T2DM) and CKD. The aim of this randomized, cross-over, open-label controlled clinical trial is to compare the glycemic response to intensive insulin treatment with NPH insulin or insulin glargine in T2DM patients and CKD stages 3 and 4. The primary efficacy end point was change in A1C from baseline. Thirty-four patients were randomized to receive insulin glargine once a day or NPH insulin, three times a day. Insulin lispro was prescribed as prandial insulin to both groups. After six months, patients switched to the other insulin therapy group. Laboratory tests were performed at baseline at 12, 24, 36 and 48 weeks. A continuous glucose monitoring system was implemented after 24 weeks and at the end of protocol. Results: Total of 29 subjects have completed the two branches of study, 2 patients dropped out due to low compliance and other 3 patients as a result of adverse events (1 death, 1 ingress on dialysis program, 1 cardiovascular event; all of them were on NPH therapy). After 24 weeks, average of A1c decreased on glargine group compared to baseline 8,86 ± 1,4% to 7,95 ± 1,1% (p=0,0285), but this difference was not observed on NPH group. There were no differences of insulin doses between both groups. Glargine group showed a tendency of lower risk of nocturnal hypoglycemia compared to NPH group (p=0,046). Conclusion: Insulin glargine improved glycemic control by reducing HbA1c without gain weight and with reduced tendency toward nocturnal hypoglycemic events compared with NPH insulin Automonitorização da glicemia Diabetes mellitus Falência renal crônica Hemoglobina A glicosilada Hipoglicemia Insuficiência renal crônica Nefropatias Terapêutica Blood glucose self-monitoring Chronic kidney failure Diabetes mellitus Hemoglobin A glycosylated Hypoglycemia Kidney disease Renal insufficiency Therapeutics
34	Influência do polimorfismo do gene MYH9 na doença renal progressiva em pacientes com nefrite lúpica / Influence of the MYH9 gene polymorphism in progressive kidney disease in patients with lupus nephritis Vinicius Sardão Colares 20 January 2012 (has links) INTRODUÇÃO: A nefrite lúpica é uma complicação frequente e de alta morbimortalidade do lúpus eritematoso sistêmico (LES). A evolução para insuficiência renal crônica terminal varia entre 8 e 15% dos casos, após um período de 5 anos. A fase inicial da nefrite se deve a uma atividade imunológica exacerbada que leva a sequelas renais, como a fibrose intersticial, sinéquias glomerulares, e glomeruloesclerose. Uma vez instalada, vários fatores aceleram a velocidade de progressão da insuficiência renal, como a presença de proteinúria residual, hipertensão arterial sistêmica e a etnia do paciente. Estudos recentes mostraram que a presença de polimorfismos do MYH9 são altamente prevalentes em pacientes com GESF (glomeruloesclerose focal e segmentar), nefropatia do HIV e em pacientes com doença renal crônica não diabética. Os polimorfismos do MYH9 mais relacionados com essas doenças são os do haplótipo E1, causados pelos polimorfismos rs4821480, rs2032487, rs4821481 e rs3752462, presentes principalmente na população negra e de hispano-americanos. No Brasil não há estudos sobre a prevalência desse gene. MÉTODOS: Nosso estudo analisou retrospectivamente 196 pacientes com nefrite lúpica, acompanhadas no ambulatório de glomerulopatias do Hospital das Clínicas da USP. Foram recuperados os dados clínicos e laboratoriais dos pacientes de janeiro de 1999 a dezembro de 2010. Foi feita análise dos polimorfismos do haplótipo E1 do gene do MYH9 (rs4821480, rs2032487, rs4821481 e rs3752462) e correlacionados com suas características clínicas e laboratoriais, apresentando como desfecho a duplicação da creatinina ou a evolução para doença renal crônica terminal. RESULTADOS: O tempo de seguimento médio dos pacientes foi de 6,1 anos, com a creatinina inicial média de 1,6 g/dL e proteinúria média de 3,9 g/dia. Dezenove pacientes não recuperaram função renal, mantendo-se em diálise. Dos 177 pacientes restantes 43 (24%) apresentaram o desfecho de duplicação (DC) da creatinina, ou necessidade de diálise (DRCT). Pacientes progressores eram tinham maior SLEDAI renal (10 vs 8,9 p=0,04), maior índice de cronicidade renal à biópsia (5 vs 2, p<0,001) e maior frequência de reativações da doença renal (flare renal) (82,9% x 53,8%, p=0,002), assim menores índices de remissão completa ou parcial (p<0,0001). Os 4 polimorfismos se segregam em conjunto, ou seja, como um haplótipo, pelo modelo de Hardy-Weinberg. Analisando separadamente cada polimorfismo, apenas o rs3752462, apresenta associação com o desfecho DC/DRCT, na análise por genótipo (CC/CT/TT, p=0,03) e quando feita análise TT/CT vs CC (p=0,02). Não houve relação dos polimorfismos com a etnia negra ou parda. Pacientes com haplótipo E1 eram progressores em 28% dos casos, conferindo um OR de 1,79 (IC 1,02 a 3,0) de DC/DRC. DISCUSSÃO: A presença do haplótipo E1 têm alta prevalência em pacientes portadores de nefrite lúpica no Brasil, sendo fator de risco para progressão da doença renal crônica / BACKGROUND: Lupus nephritis (LN) is a frequent complication with high morbidity and mortality of systemic lupus erythematosus (SLE). Chronic renal failure is observed in 8 to 15% of the patients after 5 years of follow up. LN is an inflammatory disease after a systemic autoimmune activation. Once inflammation is shutdown several renal and nonrenal factors, such as residual proteinuria, hypertension and ethnicity of the patient, may emerge and impose to the kidney a chronic phenotype (interstitial fibrosis, glomerular adhesions and glomerulosclerosis. Recently E1 haplotype (rs4821480, rs2032487, rs4821481 and rs3752462 polymorphisms) of the MYH9 gene was associated to progressive kidney diseases in patients with FSGS (focal segmental glomerulosclerosis), HIV nephropathy and non-diabetic chronic kidney disease, in african american and spanic american patients. In Brazil there is no data on this subject. METHODS: Retrospective analysis of 196 patients with LN followed in our outpatient glomerular disease ward were enrolled glomerulopathies. Patients clinical data from January 1999 to December 2010 were retrieved and MYH9 rs4821480, rs2032487, rs4821481 and rs3752462 polymorphisms were genotyped. Outcome was defined as doubling of serum creatinine, or end stage renal disease (ESRD). RESULTS: The mean follow-up of patients was 6.1 years, with an initial mean creatinine of 1.6 g/dL and mean proteinuria 3.9 g/day. On enrollment nineteen patients were on dialysis and did not recover renal function, they were withdraw from analyses of progressive kidney disease. On follow up, from 177 remaining patients, 43 (24%) showed the composite outcome: dialysis, or doubling creatinine. Progressors had higher renal SLEDAI (10 vs 8.9, p = 0.04), higher chronicity index at biopsy (5 vs 2, p <0.001) and more frequently renal flares (82, 9% vs. 53.8%, p=0.002), as well as lower rates of complete or partial remission (p <0.0001). The four polymorphisms segregate as a haplotype, according the Hardy-Weinberg model. Analysing each polymorphism, only TT/CT genotype from rs3752462 polymorphism was associated with the outcome of DC/ESRD (p = 0.02). E1 haplotype were associated with progression with an OR of 1.79 (CI 1.02 to 3.0). DISCUSSION: The presence of the E1 haplotype is associated with worse prognosis of chronic renal failure in lupus nephritis patients Cadeias pesadas de miosina Falência renal crônica Lúpus eritematoso sistêmico MYH9 Nefrite lúpica Polimorfismo de um único nucleotídeo Chronic kidney failure Lupus nephritis MYH9 Myosin heavy chains Single nucleotide polymorphism Systemic lupus erythematosus
35	Impacto do reprocessamento de dialisadores de alto fluxo e alta eficiência sobre o transporte de solutos em sessões de hemodiafiltração online curta diária / Reprocessing high-flux, high-efficiency polysulfone dialyzers on solutes removal in short daily online hemodiafiltration Melo, Natália Corrêa Vieira de 05 December 2013 (has links) Introdução: Não há estudos que avaliem o impacto da reutilização do dialisador na remoção de solutos em sessões de hemodiafiltração online curta diária (HDF-OL-D). Objetivo: Avaliar o impacto do reuso do dialisador na dose do tratamento, na cinética de beta2-microglobulina e na extração de solutos em sessões de HDF-OL-D e comparar com sessões de hemodiálise curta diária de alto fluxo (HD-D). Métodos: Foram incluídos 14 pacientes do programa de HD-D. Foram coletadas amostras de sangue pré, no meio e pós-diálise e amostras do dialisato no 1º, 7º e 13º usos do dialisador em sessões de HD-D e de HDF-OL-D. Resultados: A massa total extraída (MTDQ) e a depuração (KDQ) diretamente quantificada dos solutos pequenos (ureia, fósforo, creatinina e ácido úrico), bem como a dose de diálise ofertada, foram semelhantes quando o 1º, 7º e 13º usos do dialisador em sessões de HD-D foram comparados, respectivamente, ao 1º, 7º e 13º usos em sessões de HDF-OL-D. A MTDQ e a KDQ dos solutos pequenos e a dose de diálise foram semelhantes entre os usos do dialisador tanto em sessões de HD-D e quanto em sessões de HDF-OL-D. A MTDQ, a KDQ e o Kt/V diretamente quantificado (Kt/VDQ) de beta2-microglobulina foram maiores em sessões de HDF-OL-D do que nos respectivos usos do dialisador em sessões de HD-D. Não houve diferença quanto à cinética de beta2-microglobulina, avaliada pela MTDQ, KDQ ou Kt/VDQ, entre o 1º, 7º e 13º usos do dialisador em sessões de HD-D nem em sessões de HDF-OL-D. Na HDF-OL-D, a perda intradialítica de albumina foi significativamente diferente entre os usos do dialisador (p < 0,001), estando reduzida no 7º e 13º usos, quando comparados ao 1º uso do dialisador. Não houve correlação entre o volume de enchimento do dialisador e a MTDQ e a KDQ de moléculas pequenas em nenhum dos métodos dialíticos estudados. Em sessões de HDF-OL-D, foi observada uma correlação fraca entre o volume de enchimento do dialisador e a KDQ de beta2-microglobulina, não percebida com a MTDQ ou o Kt/VDQ de beta2-microglobulina. Conclusão: O reprocessamento de dialisadores de alto fluxo e alta eficiência não resulta em comprometimento da dose do tratamento, da cinética de beta2-microglobulina nem da extração de solutos em sessões de HDF-OL-D. A extração de beta2-microglobulina foi maior em sessões de HDF-OL-D do que em sessões de HD-D, sem diferenças significativas na remoção dos demais solutos. O reprocessamento do filtro, em sessões de HDF-OL-D, resultou numa redução significativa da perda intradialítica de albumina. Não parece haver influência do volume de enchimento do filtro na extração de solutos em nenhum dos métodos de diálise estudados / Introduction: There no studies evaluating the impact of dialyzer reutilization on solute removal in daily online hemodiafiltration (D-OL-HDF) sessions. Objectives: Our aim was to evaluate the impact of dialyzer reuse on solute extraction, beta2-microglobulin kinetics and dialysis dose in D-OL-HDF and compare to those in high-flux short daily hemodialysis (D-HD). Methods: 14 patients undergoing a D-HD program were included. Pre, middle and post-dialysis blood samples and effluent dialysate were collected in the 1st, 7th and 13th dialyzer uses in D-HD sessions and in D-OL-HDF sessions. Results: Directly quantified small solute (urea, phosphorus, creatinine and uric acid) total mass removal (TMDQ) and clearance (KDQ), as well as dialysis dosis, were similar when the 1st, 7th and 13th dialyzer D-HD uses were compared to the 1st, 7th and 13th D-OL-HDF uses. TMDQ and KDQ of small solutes and dialysis dose were similar among dialyzer uses in D-HD sessions and also in D-OL-HDF sessions. beta2-microglobulin TMDQ, KDQ and directly quantified Kt/V (Kt/VDQ) were statistically higher in D-OL-HDF dialyzer uses than in the respective D-HD uses. There was no difference in beta2-microglobulin kinetics, evaluated by TMDQ, KDQ or Kt/VDQ, among 1st, 7th and 13th uses in D-OL-HDF sessions or in D-HD sessions. In D-OL-HDF, albumin loss was significantly different among studied dialyzer uses (p < 0.001), being reduced in the 7th and 13th dialyzer uses, when compared to the first use. There was no correlation between dialyzer priming volume and small molecules TMDQ, KDQ in neither analyzed dialytic method. In D-OL-HDF sessions, it was observed a week correlation between dialyzer priming volume and beta2-microglobulin KDQ, not observed with beta2-microglobulin MTDQ or Kt/VDQ. Conclusion: High flux, high efficiency dialyzer reprocessing did not did result in a reduction of the offered dialysis dose, beta2-microglobulin kinetics or solute extraction in D-OL-HDF. beta2-microglobulin removal was greater in D-OL-HDF than in D-HD sessions, without difference in other solutes extraction. There was a significant reduction in intradialytic albumin loss with dialyzer reprocessing in D-OL-HDF sessions. Dialyzer priming volume does not appear to influence solute removal in neither analyzed dialytic method beta 2-Microglobulin/blood Chronic kidney failure Diálise renal/métodos Dialysis solutions/chemistry Falência renal crônica Hemodiafiltração/métodos Hemodiafiltration/methods Hemodialysis solutions/adverse effects Hemodialysis solutions/chemistry Microglobulina-2 beta/sangue Renal dialysis/methods Soluções para diálise/química Soluções para hemodiálise/química Urea/blood Ureia/sangue
36	Impacto do reprocessamento de dialisadores de alto fluxo e alta eficiência sobre o transporte de solutos em sessões de hemodiafiltração online curta diária / Reprocessing high-flux, high-efficiency polysulfone dialyzers on solutes removal in short daily online hemodiafiltration Natália Corrêa Vieira de Melo 05 December 2013 (has links) Introdução: Não há estudos que avaliem o impacto da reutilização do dialisador na remoção de solutos em sessões de hemodiafiltração online curta diária (HDF-OL-D). Objetivo: Avaliar o impacto do reuso do dialisador na dose do tratamento, na cinética de beta2-microglobulina e na extração de solutos em sessões de HDF-OL-D e comparar com sessões de hemodiálise curta diária de alto fluxo (HD-D). Métodos: Foram incluídos 14 pacientes do programa de HD-D. Foram coletadas amostras de sangue pré, no meio e pós-diálise e amostras do dialisato no 1º, 7º e 13º usos do dialisador em sessões de HD-D e de HDF-OL-D. Resultados: A massa total extraída (MTDQ) e a depuração (KDQ) diretamente quantificada dos solutos pequenos (ureia, fósforo, creatinina e ácido úrico), bem como a dose de diálise ofertada, foram semelhantes quando o 1º, 7º e 13º usos do dialisador em sessões de HD-D foram comparados, respectivamente, ao 1º, 7º e 13º usos em sessões de HDF-OL-D. A MTDQ e a KDQ dos solutos pequenos e a dose de diálise foram semelhantes entre os usos do dialisador tanto em sessões de HD-D e quanto em sessões de HDF-OL-D. A MTDQ, a KDQ e o Kt/V diretamente quantificado (Kt/VDQ) de beta2-microglobulina foram maiores em sessões de HDF-OL-D do que nos respectivos usos do dialisador em sessões de HD-D. Não houve diferença quanto à cinética de beta2-microglobulina, avaliada pela MTDQ, KDQ ou Kt/VDQ, entre o 1º, 7º e 13º usos do dialisador em sessões de HD-D nem em sessões de HDF-OL-D. Na HDF-OL-D, a perda intradialítica de albumina foi significativamente diferente entre os usos do dialisador (p < 0,001), estando reduzida no 7º e 13º usos, quando comparados ao 1º uso do dialisador. Não houve correlação entre o volume de enchimento do dialisador e a MTDQ e a KDQ de moléculas pequenas em nenhum dos métodos dialíticos estudados. Em sessões de HDF-OL-D, foi observada uma correlação fraca entre o volume de enchimento do dialisador e a KDQ de beta2-microglobulina, não percebida com a MTDQ ou o Kt/VDQ de beta2-microglobulina. Conclusão: O reprocessamento de dialisadores de alto fluxo e alta eficiência não resulta em comprometimento da dose do tratamento, da cinética de beta2-microglobulina nem da extração de solutos em sessões de HDF-OL-D. A extração de beta2-microglobulina foi maior em sessões de HDF-OL-D do que em sessões de HD-D, sem diferenças significativas na remoção dos demais solutos. O reprocessamento do filtro, em sessões de HDF-OL-D, resultou numa redução significativa da perda intradialítica de albumina. Não parece haver influência do volume de enchimento do filtro na extração de solutos em nenhum dos métodos de diálise estudados / Introduction: There no studies evaluating the impact of dialyzer reutilization on solute removal in daily online hemodiafiltration (D-OL-HDF) sessions. Objectives: Our aim was to evaluate the impact of dialyzer reuse on solute extraction, beta2-microglobulin kinetics and dialysis dose in D-OL-HDF and compare to those in high-flux short daily hemodialysis (D-HD). Methods: 14 patients undergoing a D-HD program were included. Pre, middle and post-dialysis blood samples and effluent dialysate were collected in the 1st, 7th and 13th dialyzer uses in D-HD sessions and in D-OL-HDF sessions. Results: Directly quantified small solute (urea, phosphorus, creatinine and uric acid) total mass removal (TMDQ) and clearance (KDQ), as well as dialysis dosis, were similar when the 1st, 7th and 13th dialyzer D-HD uses were compared to the 1st, 7th and 13th D-OL-HDF uses. TMDQ and KDQ of small solutes and dialysis dose were similar among dialyzer uses in D-HD sessions and also in D-OL-HDF sessions. beta2-microglobulin TMDQ, KDQ and directly quantified Kt/V (Kt/VDQ) were statistically higher in D-OL-HDF dialyzer uses than in the respective D-HD uses. There was no difference in beta2-microglobulin kinetics, evaluated by TMDQ, KDQ or Kt/VDQ, among 1st, 7th and 13th uses in D-OL-HDF sessions or in D-HD sessions. In D-OL-HDF, albumin loss was significantly different among studied dialyzer uses (p < 0.001), being reduced in the 7th and 13th dialyzer uses, when compared to the first use. There was no correlation between dialyzer priming volume and small molecules TMDQ, KDQ in neither analyzed dialytic method. In D-OL-HDF sessions, it was observed a week correlation between dialyzer priming volume and beta2-microglobulin KDQ, not observed with beta2-microglobulin MTDQ or Kt/VDQ. Conclusion: High flux, high efficiency dialyzer reprocessing did not did result in a reduction of the offered dialysis dose, beta2-microglobulin kinetics or solute extraction in D-OL-HDF. beta2-microglobulin removal was greater in D-OL-HDF than in D-HD sessions, without difference in other solutes extraction. There was a significant reduction in intradialytic albumin loss with dialyzer reprocessing in D-OL-HDF sessions. Dialyzer priming volume does not appear to influence solute removal in neither analyzed dialytic method Diálise renal/métodos Falência renal crônica Hemodiafiltração/métodos Microglobulina-2 beta/sangue Soluções para diálise/química Soluções para hemodiálise/química Ureia/sangue beta 2-Microglobulin/blood Chronic kidney failure Dialysis solutions/chemistry Hemodiafiltration/methods Hemodialysis solutions/adverse effects Hemodialysis solutions/chemistry Renal dialysis/methods Urea/blood
37	O efeito do laser de baixa intensidade na fibrose intersticial renal Oliveira, Fabiana Aparecida Mayrink de 24 February 2011 (has links) Submitted by Renata Lopes (renatasil82@gmail.com) on 2016-07-18T17:29:53Z No. of bitstreams: 1 fabianaaparecidamayrinkdeoliveira.pdf: 602450 bytes, checksum: 44abccc7edd994e7c93876d1aac063dd (MD5) / Approved for entry into archive by Adriana Oliveira (adriana.oliveira@ufjf.edu.br) on 2016-07-22T15:11:02Z (GMT) No. of bitstreams: 1 fabianaaparecidamayrinkdeoliveira.pdf: 602450 bytes, checksum: 44abccc7edd994e7c93876d1aac063dd (MD5) / Made available in DSpace on 2016-07-22T15:11:02Z (GMT). No. of bitstreams: 1 fabianaaparecidamayrinkdeoliveira.pdf: 602450 bytes, checksum: 44abccc7edd994e7c93876d1aac063dd (MD5) Previous issue date: 2011-02-24 / CAPES - Coordenação de Aperfeiçoamento de Pessoal de Nível Superior / FAPEMIG - Fundação de Amparo à Pesquisa do Estado de Minas Gerais / Justificativa e Objetivo: Independente da etiologia, a doença renal crônica (DRC) envolve fibrose generalizada e progressiva do tecido, atrofia tubular e a perda da função renal. Atualmente, as terapias eficazes para esta condição são escassas. Neste estudo, foram investigados os efeitos da terapia laser de baixa intensidade (LLLT) sobre a fibrose intersticial, que ocorre após obstrução ureteral unilateral (OUU) em ratos, um modelo experimental de doença renal crônica. Materiais e Métodos: Foram utilizados 32 ratos Wistar, 8 em cada grupo, machos, com 250 a 300g de peso aproximadamente e 8 semanas de idade. O rim obstruído de metade dos ratos, submetidos à OUU receberam dose única intra-operatória do LLLT (AlGaAs laser, 780 nm, 22,5 J / cm ², 30 mW, 30 segundos em cada um dos nove pontos). Após 14 dias, a fibrose renal foi avaliada pela coloração por picrosírius e medição da área transversal sob luz polarizada. Análise imunohistoquímica quantificou células do tecido renal que expressam marcadores de fibroblastos (FSP-1) e miofibroblastos (α-SMA). RT-PCR foi realizado para determinar a expressão de mRNA de genes chaves relacionados com a fibrose: TGF-β1, Smad3 e colágeno I (Col I). Resultados: No grupo OUU e tratado pelo LLLT os animais apresentaram menos fibrose renal do que os animais obstruídos (OUU). α-SMA, TGF-β1 e Smad3 foram aumentados no interstício renal de ratos OUU. LLLT reduziu a expressão de todas essas moléculas. LLLT não parece ter um efeito significativo no Col I ou FSP-1, que também foram induzidos por OUU. Conclusão: Pela primeira vez, nós mostramos que LLLT tem um efeito protetor em relação à fibrose intersticial renal. Entende-se que, atenuando a inflamação, a laserterapia pode impedir a ativação tubular e transdiferenciação, que são os dois processos principais que formam a fibrose renal no modelo OUU. / Background and Objective: Regardless of the etiology, chronic kidney disease (CKD) involves progressive widespread tissue fibrosis, tubular atrophy and loss of kidney function. At present, effective therapies to this condition are lacking. We investigated the effects of low level laser therapy (LLLT) on the interstitial fibrosis that occurs after unilateral ureteral obstruction (UUO) in rats, an experimental model of CKD. Study Design/Materials and Methods: We used 32 Wistar rats, 8 in each group, males, 250 to 300g weight and 8 weeks old. The occluded kidney of half of the Wistar rats that underwent UUO received a single intraoperative dose of LLLT (AlGaAs laser, 780 nm, 22.5 J/cm², 30 mW, 30 seconds on each of nine points). After 14 days, renal fibrosis was assessed by Sirius red staining and measurement of the cross-sectional area under polarized light. Immunohistochemical analyses quantitated the renal tissue cells that expressed fibroblast (FSP-1) and myofibroblast (α-SMA) markers. RT-PCR was performed to determine the mRNA expression of key fibrosis-related genes, namely TGF-β1, Smad3 and collagen I (Col I). Results: The UUO-LLLT animals had less severe renal fibrosis than OUU animals. α- SMA, TGF-β1 and Smad3 were increased in the renal interstitium of UUO rats. LLLT reduced the expression of all of these molecules. LLLT did not appear to have a significant effect on Col I or FSP-1, which were also induced by UUO. Conclusion: For the first time, we showed LLLT had a protective effect regarding renal interstitial fibrosis. It is conceivable that by attenuating inflammation, LLLT can prevent tubular activation and transdifferentiation, which are the two processes that mainly drive the renal fibrosis of the UUO model. CNPQ::CIENCIAS DA SAUDE Terapia de laser de baixa intensidade Obstrução ureteral Fibrose renal Doença renal crônica Fator transformador de crescimento beta Proteínas smad Alfa-actina de músculo liso Low-level laser therapy Ureteral obstruction Renal fibrosis Chronic kidney failure Transforming growth factor beta Smad proteins Alfa-smooth muscle actin
38	BIRTHWEIGHT AND SUSCEPTIBILITY TO CHRONIC DISEASE Issa Al Salmi Unknown Date (has links) The thesis examines the relationship of birthweight to risk factors and markers, such as proteinuria and glomerular filtration rate, for chronic disease in postnatal life. It made use of the Australian Diabetes, Obesity and Lifestyle Study (AusDiab). The AusDiab study is a cross sectional study where baseline data on 11,247 participants were collected in 1999-2000. Participants were recruited from a stratified sample of Australians aged ≥ 25 years, residing in 42 randomly selected urban and non-urban areas (Census Collector Districts) of the six states of Australia and the Northern Territory. The AusDiab study collected an enormous amount of clinical and laboratory data. During the 2004-05 follow-up AusDiab survey, questions about birthweight were included. Participants were asked to state their birthweight, the likely accuracy of the stated birthweight and the source of their stated birthweight. Four hundred and twelve chronic kidney disease (CKD) patients were approached, and 339 agreed to participate in the study. The patients completed the same questionnaire. Medical records were reviewed to check the diagnoses, causes of kidney trouble and SCr levels. Two control subjects, matched for gender and age, were selected for each CKD patient from participants in the AusDiab study who reported their birthweight. Among 7,157 AusDiab participants who responded to the questionnaire, 4,502 reported their birthweights, with a mean (standard deviation) of 3.4 (0.7) kg. The benefit and disadvantages of these data are discussed in chapter three. The data were analysed for the relationship between birthweight and adult body size and composition, disorders of glucose regulation, blood pressure, lipid abnormalities, cardiovascular diseases and glomerular filtration rate. Low birthweight was associated with smaller body build and lower lean mass and total body water in both females and males. In addition low birthweight was associated with central obesity and higher body fat percentage in females, even after taking into account current physical activity and socioeconomic status. Fasting plasma glucose, post load glucose and glycosylated haemoglobin were strongly and inversely correlated with birthweight. In those with low birthweight (< 2.5 kg), the risks for having impaired fasting glucose, impaired glucose tolerance, diabetes and all abnormalities combined were increased by 1.75, 2.22, 2.76 and 2.28 for females and by 1.40, 1.32, 1.98 and 1.49 for males compared to those with normal birthweight (≥ 2.5 kg), respectively. Low birthweight individuals were at higher risk for having high blood pressure ≥ 140/90 mmHg and ≥ 130/85 mmHg compared to those with normal birthweight. People with low birthweight showed a trend towards increased risk for high cholesterol (≥ 5.5 mmol/l) compared to those of normal birthweight. Females with low birthweight had increased risk for high low density lipoprotein cholesterol (≥ 3.5 mmol/l) and triglyceride levels (≥ 1.7 mmol/l) when compared to those with normal birthweight. Males with low birthweight exhibited increased risk for low levels of high density lipoprotein cholesterol (<0.9 mmol/l) than those with normal birthweight. Females with low birthweight were at least 1.39, 1.40, 2.30 and 1.47 times more likely to have angina, coronary artery disease, stroke and overall cardiovascular diseases respectively, compared to those ≥ 2.5 kg. Similarly, males with low birthweight were 1.76, 1.48, 3.34 and 1.70 times more likely to have angina, coronary artery disease, stroke and overall cardiovascular diseases compared to those ≥ 2.5 kg, respectively. The estimated glomerular filtration rate was strongly and positively associated with birthweight, with a predicted increase of 2.6 ml/min (CI 2.1, 3.2) and 3.8 (3.0, 4.5) for each kg of birthweight for females and males, respectively. The odd ratio (95% confidence interval) for low glomerular filtration rate (<61.0 ml/min for female and < 87.4 male) in people of low birthweight compared with those of normal birthweight was 2.04 (1.45, 2.88) for female and 3.4 (2.11, 5.36) for male. One hundred and eighty-nineCKD patients reported their birthweight; 106 were male. Their age was 60.3(15) years. Their birthweight was 3.27 (0.62) kg, vs 3.46 (0.6) kg for their AusDiab controls, p<0.001 and the proportions with birthweight<2.5 kg were 12.17% and 4.44%, p<0.001. Among CKD patients, 22.8%, 21.7%, 18% and 37.6% were in CKD stages 2, 3, 4 and 5 respectively. Birthweights by CKD stage and their AusDiab controls were as follows: 3.38 (0.52) vs 3.49 (0.52), p=0.251 for CKD2; 3.28 (0.54) vs 3.44 (0.54), p=0.121 for CKD3; 3.19 (0.72) vs 3.43 (0.56), p= 0.112 for CKD4 and 3.09 (0.65) vs 3.47 (0.67), p<0.001 for CKD5. The results demonstrate that in an affluent Western country with a good adult health profile, low birthweight people were predisposed to higher rates of glycaemic dysregulation, high blood pressure, dyslipidaemia, cardiovascular diseases and lower glomerular filtration rate in adult life. In all instances it would be prudent to adopt policies of intensified whole of life surveillance of lower birthweight people, anticipating this risk. The general public awareness of the effect of low birthweight on development of chronic diseases in later life is of vital importance. The general public, in addition to the awareness of people in medical practice of the role of low birthweight, will lead to a better management of this group of our population that is increasingly surviving into adulthood. birth weight birthweight birth weight and renal volume BIRTH WEIGHT QUESTIONNAIRE chronic disease Barker Hypothesis Foetal development DOHaD gestational age Anthropometric Characteristics body composition Height weight body mass index Waist Circumference hip circumference Waist-hip Ratio obesity Central Obesity Fatness Lean Body Mass Lean Mass Fat Mass body fat mass Body Fat Percentage body fatness Body Surface Area diabetes Fasting Glucose fasting insulin level glucose tolerance Impaired Fasting Glucose Impaired Glucose Tolerance Glycosylated Hemoglobin HbA1c IFG glucose control glycaemic control Metabolic Syndrome Syndrome X blood pressure Systolic Blood-pressure Diastolic Blood-pressure Systolic Hypertension high blood pressure Hypertension Dyslipidaemia Dyslipidemia Total Cholesterol Triglyceride Low Density Lipoprotein Cholesterol Ldl Cholesterol High Density Lipoprotein Hdl Cholesterol Fibrinogen angina Angina-pectoris Stroke coronary artery disease cardiovascular disease Framingham Framingham Heart Study Framingham Score coronary heart disease Glomerular Filtration glomerular filtration rate Glomerular Hyperfiltration Glomerular Injury Glomerular Number Nephrogenesis Nephron Endowment Nephron Number NKF-K/DQQI Classification Chronic Kidney Disease (ckd) Chronic Kidney Failure Kidney Failure CKD STAGES end-stage renal disease (ESRD) end-stage renal failure Cockcroft-gault MDRD formula Serum Creatinine Urinary Creatinine albuminuria Albuminuria:creatinine Ratio Kidney Development Kidney dysfunction low birth weight low birth weight Pre-term Birth AusDiab Study case control longitudinal observational study
39	BIRTHWEIGHT AND SUSCEPTIBILITY TO CHRONIC DISEASE Issa Al Salmi Unknown Date (has links) The thesis examines the relationship of birthweight to risk factors and markers, such as proteinuria and glomerular filtration rate, for chronic disease in postnatal life. It made use of the Australian Diabetes, Obesity and Lifestyle Study (AusDiab). The AusDiab study is a cross sectional study where baseline data on 11,247 participants were collected in 1999-2000. Participants were recruited from a stratified sample of Australians aged ≥ 25 years, residing in 42 randomly selected urban and non-urban areas (Census Collector Districts) of the six states of Australia and the Northern Territory. The AusDiab study collected an enormous amount of clinical and laboratory data. During the 2004-05 follow-up AusDiab survey, questions about birthweight were included. Participants were asked to state their birthweight, the likely accuracy of the stated birthweight and the source of their stated birthweight. Four hundred and twelve chronic kidney disease (CKD) patients were approached, and 339 agreed to participate in the study. The patients completed the same questionnaire. Medical records were reviewed to check the diagnoses, causes of kidney trouble and SCr levels. Two control subjects, matched for gender and age, were selected for each CKD patient from participants in the AusDiab study who reported their birthweight. Among 7,157 AusDiab participants who responded to the questionnaire, 4,502 reported their birthweights, with a mean (standard deviation) of 3.4 (0.7) kg. The benefit and disadvantages of these data are discussed in chapter three. The data were analysed for the relationship between birthweight and adult body size and composition, disorders of glucose regulation, blood pressure, lipid abnormalities, cardiovascular diseases and glomerular filtration rate. Low birthweight was associated with smaller body build and lower lean mass and total body water in both females and males. In addition low birthweight was associated with central obesity and higher body fat percentage in females, even after taking into account current physical activity and socioeconomic status. Fasting plasma glucose, post load glucose and glycosylated haemoglobin were strongly and inversely correlated with birthweight. In those with low birthweight (< 2.5 kg), the risks for having impaired fasting glucose, impaired glucose tolerance, diabetes and all abnormalities combined were increased by 1.75, 2.22, 2.76 and 2.28 for females and by 1.40, 1.32, 1.98 and 1.49 for males compared to those with normal birthweight (≥ 2.5 kg), respectively. Low birthweight individuals were at higher risk for having high blood pressure ≥ 140/90 mmHg and ≥ 130/85 mmHg compared to those with normal birthweight. People with low birthweight showed a trend towards increased risk for high cholesterol (≥ 5.5 mmol/l) compared to those of normal birthweight. Females with low birthweight had increased risk for high low density lipoprotein cholesterol (≥ 3.5 mmol/l) and triglyceride levels (≥ 1.7 mmol/l) when compared to those with normal birthweight. Males with low birthweight exhibited increased risk for low levels of high density lipoprotein cholesterol (<0.9 mmol/l) than those with normal birthweight. Females with low birthweight were at least 1.39, 1.40, 2.30 and 1.47 times more likely to have angina, coronary artery disease, stroke and overall cardiovascular diseases respectively, compared to those ≥ 2.5 kg. Similarly, males with low birthweight were 1.76, 1.48, 3.34 and 1.70 times more likely to have angina, coronary artery disease, stroke and overall cardiovascular diseases compared to those ≥ 2.5 kg, respectively. The estimated glomerular filtration rate was strongly and positively associated with birthweight, with a predicted increase of 2.6 ml/min (CI 2.1, 3.2) and 3.8 (3.0, 4.5) for each kg of birthweight for females and males, respectively. The odd ratio (95% confidence interval) for low glomerular filtration rate (<61.0 ml/min for female and < 87.4 male) in people of low birthweight compared with those of normal birthweight was 2.04 (1.45, 2.88) for female and 3.4 (2.11, 5.36) for male. One hundred and eighty-nineCKD patients reported their birthweight; 106 were male. Their age was 60.3(15) years. Their birthweight was 3.27 (0.62) kg, vs 3.46 (0.6) kg for their AusDiab controls, p<0.001 and the proportions with birthweight<2.5 kg were 12.17% and 4.44%, p<0.001. Among CKD patients, 22.8%, 21.7%, 18% and 37.6% were in CKD stages 2, 3, 4 and 5 respectively. Birthweights by CKD stage and their AusDiab controls were as follows: 3.38 (0.52) vs 3.49 (0.52), p=0.251 for CKD2; 3.28 (0.54) vs 3.44 (0.54), p=0.121 for CKD3; 3.19 (0.72) vs 3.43 (0.56), p= 0.112 for CKD4 and 3.09 (0.65) vs 3.47 (0.67), p<0.001 for CKD5. The results demonstrate that in an affluent Western country with a good adult health profile, low birthweight people were predisposed to higher rates of glycaemic dysregulation, high blood pressure, dyslipidaemia, cardiovascular diseases and lower glomerular filtration rate in adult life. In all instances it would be prudent to adopt policies of intensified whole of life surveillance of lower birthweight people, anticipating this risk. The general public awareness of the effect of low birthweight on development of chronic diseases in later life is of vital importance. The general public, in addition to the awareness of people in medical practice of the role of low birthweight, will lead to a better management of this group of our population that is increasingly surviving into adulthood. birth weight birthweight birth weight and renal volume BIRTH WEIGHT QUESTIONNAIRE chronic disease Barker Hypothesis Foetal development DOHaD gestational age Anthropometric Characteristics body composition Height weight body mass index Waist Circumference hip circumference Waist-hip Ratio obesity Central Obesity Fatness Lean Body Mass Lean Mass Fat Mass body fat mass Body Fat Percentage body fatness Body Surface Area diabetes Fasting Glucose fasting insulin level glucose tolerance Impaired Fasting Glucose Impaired Glucose Tolerance Glycosylated Hemoglobin HbA1c IFG glucose control glycaemic control Metabolic Syndrome Syndrome X blood pressure Systolic Blood-pressure Diastolic Blood-pressure Systolic Hypertension high blood pressure Hypertension Dyslipidaemia Dyslipidemia Total Cholesterol Triglyceride Low Density Lipoprotein Cholesterol Ldl Cholesterol High Density Lipoprotein Hdl Cholesterol Fibrinogen angina Angina-pectoris Stroke coronary artery disease cardiovascular disease Framingham Framingham Heart Study Framingham Score coronary heart disease Glomerular Filtration glomerular filtration rate Glomerular Hyperfiltration Glomerular Injury Glomerular Number Nephrogenesis Nephron Endowment Nephron Number NKF-K/DQQI Classification Chronic Kidney Disease (ckd) Chronic Kidney Failure Kidney Failure CKD STAGES end-stage renal disease (ESRD) end-stage renal failure Cockcroft-gault MDRD formula Serum Creatinine Urinary Creatinine albuminuria Albuminuria:creatinine Ratio Kidney Development Kidney dysfunction low birth weight low birth weight Pre-term Birth AusDiab Study case control longitudinal observational study
40	BIRTHWEIGHT AND SUSCEPTIBILITY TO CHRONIC DISEASE Issa Al Salmi Unknown Date (has links) The thesis examines the relationship of birthweight to risk factors and markers, such as proteinuria and glomerular filtration rate, for chronic disease in postnatal life. It made use of the Australian Diabetes, Obesity and Lifestyle Study (AusDiab). The AusDiab study is a cross sectional study where baseline data on 11,247 participants were collected in 1999-2000. Participants were recruited from a stratified sample of Australians aged ≥ 25 years, residing in 42 randomly selected urban and non-urban areas (Census Collector Districts) of the six states of Australia and the Northern Territory. The AusDiab study collected an enormous amount of clinical and laboratory data. During the 2004-05 follow-up AusDiab survey, questions about birthweight were included. Participants were asked to state their birthweight, the likely accuracy of the stated birthweight and the source of their stated birthweight. Four hundred and twelve chronic kidney disease (CKD) patients were approached, and 339 agreed to participate in the study. The patients completed the same questionnaire. Medical records were reviewed to check the diagnoses, causes of kidney trouble and SCr levels. Two control subjects, matched for gender and age, were selected for each CKD patient from participants in the AusDiab study who reported their birthweight. Among 7,157 AusDiab participants who responded to the questionnaire, 4,502 reported their birthweights, with a mean (standard deviation) of 3.4 (0.7) kg. The benefit and disadvantages of these data are discussed in chapter three. The data were analysed for the relationship between birthweight and adult body size and composition, disorders of glucose regulation, blood pressure, lipid abnormalities, cardiovascular diseases and glomerular filtration rate. Low birthweight was associated with smaller body build and lower lean mass and total body water in both females and males. In addition low birthweight was associated with central obesity and higher body fat percentage in females, even after taking into account current physical activity and socioeconomic status. Fasting plasma glucose, post load glucose and glycosylated haemoglobin were strongly and inversely correlated with birthweight. In those with low birthweight (< 2.5 kg), the risks for having impaired fasting glucose, impaired glucose tolerance, diabetes and all abnormalities combined were increased by 1.75, 2.22, 2.76 and 2.28 for females and by 1.40, 1.32, 1.98 and 1.49 for males compared to those with normal birthweight (≥ 2.5 kg), respectively. Low birthweight individuals were at higher risk for having high blood pressure ≥ 140/90 mmHg and ≥ 130/85 mmHg compared to those with normal birthweight. People with low birthweight showed a trend towards increased risk for high cholesterol (≥ 5.5 mmol/l) compared to those of normal birthweight. Females with low birthweight had increased risk for high low density lipoprotein cholesterol (≥ 3.5 mmol/l) and triglyceride levels (≥ 1.7 mmol/l) when compared to those with normal birthweight. Males with low birthweight exhibited increased risk for low levels of high density lipoprotein cholesterol (<0.9 mmol/l) than those with normal birthweight. Females with low birthweight were at least 1.39, 1.40, 2.30 and 1.47 times more likely to have angina, coronary artery disease, stroke and overall cardiovascular diseases respectively, compared to those ≥ 2.5 kg. Similarly, males with low birthweight were 1.76, 1.48, 3.34 and 1.70 times more likely to have angina, coronary artery disease, stroke and overall cardiovascular diseases compared to those ≥ 2.5 kg, respectively. The estimated glomerular filtration rate was strongly and positively associated with birthweight, with a predicted increase of 2.6 ml/min (CI 2.1, 3.2) and 3.8 (3.0, 4.5) for each kg of birthweight for females and males, respectively. The odd ratio (95% confidence interval) for low glomerular filtration rate (<61.0 ml/min for female and < 87.4 male) in people of low birthweight compared with those of normal birthweight was 2.04 (1.45, 2.88) for female and 3.4 (2.11, 5.36) for male. One hundred and eighty-nineCKD patients reported their birthweight; 106 were male. Their age was 60.3(15) years. Their birthweight was 3.27 (0.62) kg, vs 3.46 (0.6) kg for their AusDiab controls, p<0.001 and the proportions with birthweight<2.5 kg were 12.17% and 4.44%, p<0.001. Among CKD patients, 22.8%, 21.7%, 18% and 37.6% were in CKD stages 2, 3, 4 and 5 respectively. Birthweights by CKD stage and their AusDiab controls were as follows: 3.38 (0.52) vs 3.49 (0.52), p=0.251 for CKD2; 3.28 (0.54) vs 3.44 (0.54), p=0.121 for CKD3; 3.19 (0.72) vs 3.43 (0.56), p= 0.112 for CKD4 and 3.09 (0.65) vs 3.47 (0.67), p<0.001 for CKD5. The results demonstrate that in an affluent Western country with a good adult health profile, low birthweight people were predisposed to higher rates of glycaemic dysregulation, high blood pressure, dyslipidaemia, cardiovascular diseases and lower glomerular filtration rate in adult life. In all instances it would be prudent to adopt policies of intensified whole of life surveillance of lower birthweight people, anticipating this risk. The general public awareness of the effect of low birthweight on development of chronic diseases in later life is of vital importance. The general public, in addition to the awareness of people in medical practice of the role of low birthweight, will lead to a better management of this group of our population that is increasingly surviving into adulthood. birth weight birthweight birth weight and renal volume BIRTH WEIGHT QUESTIONNAIRE chronic disease Barker Hypothesis Foetal development DOHaD gestational age Anthropometric Characteristics body composition Height weight body mass index Waist Circumference hip circumference Waist-hip Ratio obesity Central Obesity Fatness Lean Body Mass Lean Mass Fat Mass body fat mass Body Fat Percentage body fatness Body Surface Area diabetes Fasting Glucose fasting insulin level glucose tolerance Impaired Fasting Glucose Impaired Glucose Tolerance Glycosylated Hemoglobin HbA1c IFG glucose control glycaemic control Metabolic Syndrome Syndrome X blood pressure Systolic Blood-pressure Diastolic Blood-pressure Systolic Hypertension high blood pressure Hypertension Dyslipidaemia Dyslipidemia Total Cholesterol Triglyceride Low Density Lipoprotein Cholesterol Ldl Cholesterol High Density Lipoprotein Hdl Cholesterol Fibrinogen angina Angina-pectoris Stroke coronary artery disease cardiovascular disease Framingham Framingham Heart Study Framingham Score coronary heart disease Glomerular Filtration glomerular filtration rate Glomerular Hyperfiltration Glomerular Injury Glomerular Number Nephrogenesis Nephron Endowment Nephron Number NKF-K/DQQI Classification Chronic Kidney Disease (ckd) Chronic Kidney Failure Kidney Failure CKD STAGES end-stage renal disease (ESRD) end-stage renal failure Cockcroft-gault MDRD formula Serum Creatinine Urinary Creatinine albuminuria Albuminuria:creatinine Ratio Kidney Development Kidney dysfunction low birth weight low birth weight Pre-term Birth AusDiab Study case control longitudinal observational study

Search results